Blueprint Medicines Corp (NASDAQ: BPMC) is -4.18% lower on its value in year-to-date trading and has touched a low of $43.89 and a high of $101.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BPMC stock was last observed hovering at around $86.09 in the last trading session, with the day’s gains setting it 2.29%.
Currently trading at $88.38, the stock is -2.26% and 0.08% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.73 million and changing 2.66% at the moment leaves the stock 27.80% off its SMA200. BPMC registered 83.10% gain for a year compared to 6-month gain of 82.57%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 1.80% loss in the last 1 month and extending the period to 3 months gives it a 11.34%, and is -2.33% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.21% over the week and 4.19% over the month.
Blueprint Medicines Corp (BPMC) has around 655 employees, a market worth around $5.41B and $249.38M in sales. Profit margin for the company is -203.30%. Distance from 52-week low is 101.37% and -12.50% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.58%).
The EPS is expected to grow by 33.13% this year
The shares outstanding are 61.15M, and float is at 59.80M with Short Float at 7.31%.
Blueprint Medicines Corp (BPMC) Insider Activity
The most recent transaction is an insider sale by Landsittel Michael, the company’s CHIEF FINANCIAL OFFICER. SEC filings show that Landsittel Michael sold 5,000 shares of the company’s common stock on Mar 28 ’24 at a price of $95.00 per share for a total of $0.47 million. Following the sale, the insider now owns 47286.0 shares.
Blueprint Medicines Corp disclosed in a document filed with the SEC on Mar 20 ’24 that Albers Jeffrey W. (Director) sold a total of 25,073 shares of the company’s common stock. The trade occurred on Mar 20 ’24 and was made at $87.28 per share for $2.19 million. Following the transaction, the insider now directly holds 0.18 million shares of the BPMC stock.
Still, SEC filings show that on Mar 15 ’24, Landsittel Michael (CHIEF FINANCIAL OFFICER) disposed off 13,734 shares at an average price of $87.78 for $1.21 million. The insider now directly holds 47,286 shares of Blueprint Medicines Corp (BPMC).
